Fidelity Advisor Biotechnology Fund Class A EBIT

The latest EBIT for FBTAX is $66M as of January 2024. That compares with $63M in the prior-year period — up 5.7% year over year. That is below the sector sector average of $2.6T. Investors often review this figure alongside Fidelity Advisor Biotechnology Fund Class A's historical trend and sector peers before judging valuation or financial health.

Over the past year, FBTAX's EBIT moved from $63M to $66M — a 5.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Fidelity Advisor Biotechnology Fund Class A's operating scale or balance-sheet position.

Against its sector companies, FBTAX currently prints $66M for EBIT, while the sector average sits near $2.6T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Fidelity Advisor Biotechnology Fund Class A's growth, margins, and balance sheet.

A EBIT figure of $66M for FBTAX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.6T. Explore the charts below for those layers of context.

After noting FBTAX's EBIT ($66M), review year-over-year change from $63M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.